GlaxoSmithKline acquires preclinical PPAR-gamma modulators from Bayer's osteoporosis research programme
Under the terms of the agreement GSK will receive patents and worldwide development and marketing rights for Bay 54-9801 and related compounds from Bayer's preclinical programme. Bayer will retain the right to claim certain compounds for its own use in the fields of cardiovascular and oncology.
"We are excited by this opportunity to build on an area of scientific strength at GSK by adding Bayer's novel PPAR-gamma modulator programme to our own expertise. Therapeutic intervention with these innovative compounds has the potential to enhance bone formation in osteoporosis, rather than affect bone loss which is targeted by current therapies", said Ken Batchelor, Senior Vice President of the Metabolic, Musculoskeletal and Viral Diseases Centre for Excellence in Drug Discovery at GSK.
"We are pleased that GlaxoSmithKline, an ideal partner in the PPAR field, will develop Bay 54-9801 in important indications such as osteoporosis. This is a further example of Bayer's strategy to focus on its key strengths and to capitalize on our strong research platform by forming partnerships with other companies" said Prof. Wolfgang Hartwig, Executive Vice President and Head of International Research at Bayer's Pharmaceuticals Business Group.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.